208 related articles for article (PubMed ID: 33122747)
21. TERT promoter mutations in melanoma survival.
Nagore E; Heidenreich B; Rachakonda S; Garcia-Casado Z; Requena C; Soriano V; Frank C; Traves V; Quecedo E; Sanjuan-Gimenez J; Hemminki K; Landi MT; Kumar R
Int J Cancer; 2016 Jul; 139(1):75-84. PubMed ID: 26875008
[TBL] [Abstract][Full Text] [Related]
22. Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma.
Takai E; Omata W; Totoki Y; Nakamura H; Shiba S; Takahashi A; Namikawa K; Mori T; Yamazaki N; Shibata T; Yachida S
Cancer Sci; 2021 Nov; 112(11):4748-4757. PubMed ID: 34477284
[TBL] [Abstract][Full Text] [Related]
23. Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.
Ashida A; Sakaizawa K; Uhara H; Okuyama R
Acta Derm Venereol; 2017 Nov; 97(10):1212-1218. PubMed ID: 28681063
[TBL] [Abstract][Full Text] [Related]
24. Development and Clinical Validation of Discriminatory Multitarget Digital Droplet PCR Assays for the Detection of Hot Spot KRAS and NRAS Mutations in Cell-Free DNA.
Hussung S; Follo M; Klar RFU; Michalczyk S; Fritsch K; Nollmann F; Hipp J; Duyster J; Scherer F; von Bubnoff N; Boerries M; Wittel U; Fritsch RM
J Mol Diagn; 2020 Jul; 22(7):943-956. PubMed ID: 32376474
[TBL] [Abstract][Full Text] [Related]
25. Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma.
Calapre L; Giardina T; Robinson C; Reid AL; Al-Ogaili Z; Pereira MR; McEvoy AC; Warburton L; Hayward NK; Khattak MA; Meniawy TM; Millward M; Amanuel B; Ziman M; Gray ES
Mol Oncol; 2019 Feb; 13(2):171-184. PubMed ID: 30312528
[TBL] [Abstract][Full Text] [Related]
26. Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor.
Mattila KE; Mäkelä S; Kytölä S; Andersson E; Vihinen P; Ramadan S; Skyttä T; Tiainen L; Vuoristo MS; Tyynelä-Korhonen K; Koivunen J; Kohtamäki L; Aittomäki K; Hernberg M
Acta Oncol; 2022 Oct; 61(10):1263-1267. PubMed ID: 36307938
[TBL] [Abstract][Full Text] [Related]
27. Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy.
Keller L; Guibert N; Casanova A; Brayer S; Farella M; Delaunay M; Gilhodes J; Martin E; Balagué G; Favre G; Pradines A; Meyer N
Acta Derm Venereol; 2019 Feb; 99(2):206-210. PubMed ID: 30393817
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations.
Ogasawara A; Hihara T; Shintani D; Yabuno A; Ikeda Y; Tai K; Fujiwara K; Watanabe K; Hasegawa K
Cancer Res Treat; 2020 Oct; 52(4):1219-1228. PubMed ID: 32599986
[TBL] [Abstract][Full Text] [Related]
29. Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy.
Haselmann V; Gebhardt C; Brechtel I; Duda A; Czerwinski C; Sucker A; Holland-Letz T; Utikal J; Schadendorf D; Neumaier M
Clin Chem; 2018 May; 64(5):830-842. PubMed ID: 29483107
[TBL] [Abstract][Full Text] [Related]
30. Ultra-deep massively parallel sequencing with unique molecular identifier tagging achieves comparable performance to droplet digital PCR for detection and quantification of circulating tumor DNA from lung cancer patients.
Tran LS; Pham HT; Tran VU; Tran TT; Dang AH; Le DT; Nguyen SL; Nguyen NV; Nguyen TV; Vo BT; Dao HT; Nguyen NH; Tran TH; Nguyen CV; Pham PC; Dang-Mai AT; Dinh-Nguyen TK; Phan VH; Do TT; Truong Dinh K; Do HN; Phan MD; Giang H; Nguyen HN
PLoS One; 2019; 14(12):e0226193. PubMed ID: 31841547
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the liquid biopsy for the detection of BRAFV600E mutation in metastatic melanoma patients.
Salvianti F; Massi D; De Giorgi V; Gori A; Pazzagli M; Pinzani P
Cancer Biomark; 2019; 26(3):271-279. PubMed ID: 31524142
[TBL] [Abstract][Full Text] [Related]
32. Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.
Carlino MS; Haydu LE; Kakavand H; Menzies AM; Hamilton AL; Yu B; Ng CC; Cooper WA; Thompson JF; Kefford RF; O'Toole SA; Scolyer RA; Long GV
Br J Cancer; 2014 Jul; 111(2):292-9. PubMed ID: 24918823
[TBL] [Abstract][Full Text] [Related]
33. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
[TBL] [Abstract][Full Text] [Related]
34. Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.
Wilson MA; Zhao F; Letrero R; D'Andrea K; Rimm DL; Kirkwood JM; Kluger HM; Lee SJ; Schuchter LM; Flaherty KT; Nathanson KL
Clin Cancer Res; 2014 Jun; 20(12):3328-37. PubMed ID: 24714776
[TBL] [Abstract][Full Text] [Related]
35. TERT, BRAF, and NRAS Mutational Heterogeneity between Paired Primary and Metastatic Melanoma Tumors.
Chang GA; Wiggins JM; Corless BC; Syeda MM; Tadepalli JS; Blake S; Fleming N; Darvishian F; Pavlick A; Berman R; Shapiro R; Shao Y; Karlin-Neumann G; Spittle C; Osman I; Polsky D
J Invest Dermatol; 2020 Aug; 140(8):1609-1618.e7. PubMed ID: 32087194
[TBL] [Abstract][Full Text] [Related]
36. Circulating Tumour DNA Reflects Tumour Burden Independently of Adverse Events Caused by Systemic Therapies for Melanoma.
Ashida A; Sakaizawa K; Mikoshiba A; Kiniwa Y; Okuyama R
Acta Derm Venereol; 2019 Nov; 99(12):1184-1185. PubMed ID: 31396634
[No Abstract] [Full Text] [Related]
37. Diversity of circulating tumor cells in peripheral blood: Detection of heterogeneous BRAF mutations in a patient with advanced melanoma by single-cell analysis.
Kiniwa Y; Nakamura K; Mikoshiba A; Akiyama Y; Morimoto A; Okuyama R
J Dermatol Sci; 2018 May; 90(2):211-213. PubMed ID: 29426605
[No Abstract] [Full Text] [Related]
38. Liquid biopsy for
Güttlein L; Luca MR; Esteso F; Fresno C; Mariani J; Otero Pizarro M; Brest E; Starapoli S; Kreimberg K; Teves P; Mendoza Bertelli A; R Girotti M; Salanova R; O'Connor JM
Future Oncol; 2022 Sep; 18(29):3277-3287. PubMed ID: 36004810
[No Abstract] [Full Text] [Related]
39. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
40. Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.
Ulivieri A; Cardillo G; Manente L; Paone G; Mancuso AP; Vigna L; Di Stasio E; Gasbarra R; Girlando S; Leone A
Oncotarget; 2015 Aug; 6(23):19868-79. PubMed ID: 26305188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
